BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
SUBSCRIBE
BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
BullScope
No Result
View All Result
Home Market News

Adobe names Chakravarthy CEO as Narayen steps to executive chair

Moe Alsumidaie by Moe Alsumidaie
September 10, 2026
in Market News
0
74
SHARES
1.2k
VIEWS
Share on XShare on LinkedInShare on Facebook

Adobe’s board has named Anil Chakravarthy president and chief executive officer effective December 1, 2026, replacing Shantanu Narayen, who will become executive chair. Chakravarthy, who has led Adobe’s Customer Experience Orchestration business and worldwide field operations since 2020, is the first external hire to reach the CEO role at the company in its history under Narayen’s 23-year tenure.

The announcement carries no new financial guidance, revenue targets, or operating margin expectations. Adobe’s most recent filed results showed FY2025 revenue growth of 10.5% and operating margin of 36.6%. The company will host its Q3 FY2026 earnings call on September 10, two days after this filing, where management may address the leadership transition’s strategic intent and any forward outlook changes.

What it means

Chakravarthy’s appointment signals Adobe’s board believes the company’s next phase requires operational leadership shaped outside the organization. His six-and-a-half-year track record at Adobe centers on the Customer Experience Orchestration segment, a business he expanded through product launches including GenStudio and CX Enterprise Coworker, both positioned as AI-native tools. The board’s language emphasizes “agentic software” and “AI-driven era”, suggesting the new CEO’s mandate is to accelerate Adobe’s pivot toward autonomous AI agents embedded in creative and productivity workflows, a category still forming and where Adobe competes against Microsoft, Salesforce, and emerging startups.

Chakravarthy’s prior role as CEO at Informatica, a data management platform company, and his experience at Symantec and VeriSign indicate the board values someone with enterprise software scaling experience outside Adobe’s historical creative-tools core. That choice implies confidence that Adobe’s creative business (Photoshop, Illustrator, Premiere) is mature enough to run without the CEO’s daily attention, and that growth will come from expanding the enterprise and AI-driven segments where Chakravarthy built his Adobe reputation.

BullScope TerminalADOBE INC. was the article. The engine is the product.Same yardsticks, any ticker: filed financials in, math-vs-mood out. Nothing here is advice; it is the evidence, organized.Run another company →

The open question the filing does not address: whether this transition reflects board concern about Adobe’s 10.5% revenue growth rate under Narayen’s final year, or whether it is a planned succession timed to Narayen’s tenure arc. Narayen’s move to executive chair, a role that typically carries advisory rather than operational authority, suggests continuity rather than crisis, but the earnings call on September 10 will be the first opportunity to hear management’s framing of the handoff and any changes to near-term strategy or margin expectations.

Source: the company’s 8-K filed 2026-09-08 with the SEC.

BullScope publishes impersonal research for a general audience. Nothing here is personalized investment advice, and nothing here is a recommendation to buy or sell any security. As of publication, neither BullScope nor its operator holds a position in any security, covered or otherwise; we do not trade at all, and we accept no compensation from any company we cover. When a conflict of interest exists, we do not publish: companies that compensate our operator in any capacity, or about which our operator could hold nonpublic information, are barred from coverage automatically, as described in the conflicts policy in our methodology. Figures come from company filings and public data through our published methodology; forecasts are conditional scenarios, not predictions and not promises. Markets carry risk, including loss of principal. Consider your own situation, or consult a licensed adviser, before acting on anything you read.

For the standing yardsticks on Adobe: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: Adobe.

BullScope TerminalYou just read ADOBE INC.’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →
Moe Alsumidaie

Moe Alsumidaie

Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.

Recommended For You

Zoetis narrows revenue outlook as U.S. companion animal sales slide, raises profit guidance on margin strength

by Moe Alsumidaie
November 6, 2026
0

Zoetis cut its full-year revenue forecast to $9.220 billion to $9.320 billion, representing organic operational decline of 2 percent to 1 p

Read moreDetails

Viatris Raises 2026 Guidance as Adjusted EBITDA Climbs 9 Percent Year to Date

by Moe Alsumidaie
November 6, 2026
0

Viatris raised the midpoints of its full-year 2026 financial guidance across all key metrics on the strength of nine-month adjusted EBITDA

Read moreDetails

Joby Aviation raises FY26 revenue outlook 15% as eIPP flights and defense contracts accelerate path to certification

by Moe Alsumidaie
November 5, 2026
0

Joby Aviation lifted its full-year 2026 revenue guidance by 15 percent and completed the first crewed eVTOL flights under the federal gover

Read moreDetails

Amgen’s revenue growth slows to 8% as biosimilar competition erodes legacy franchises

by Moe Alsumidaie
November 4, 2026
0

Amgen's third-quarter revenue rose 8% to $10.4 billion, a deceleration from the 10.0% full-year growth rate filed for fiscal 2025. The slow

Read moreDetails

Palantir’s U.S. commercial revenue overtakes government for the first time as quarterly sales accelerate to 96% growth

by Moe Alsumidaie
November 3, 2026
0

Palantir Technologies raised full-year revenue guidance to 91% growth after U.S. commercial revenue surpassed U.S. government revenue in th

Read moreDetails
Next Post

Indivior: Earnings Have Turned Positive. The Multiple Has Not Yet Moved in Step.

Please login to join discussion
BullScope
The Research Terminal
Run any stock through the BullScope evidence engine. Filings in, evidence out. Every number explains itself.
Open the Terminal
A BullScope product

Related News

Hill or Cliff? The One Exchange That Defines Merck Right Now

August 5, 2026

Vericel: The Company That Finally Started Making Money Is Priced Like It Stopped

November 4, 2026

Abbott Is Beating Its Targets. The Stock Is Down 23%. The Gap Is the Story.

September 21, 2026
BullScope

BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.

Prefer BullScope.ai on Google

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

No Result
View All Result
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.